Currently out of the existing stock ratings of Jason Wittes, 58 are a BUY (84.06%), 11 are a HOLD (15.94%).

Jason Wittes

Work Performance Price Targets & Ratings Chart

Analyst Jason Wittes works at LOOP CAPITAL with a stock forecast success ratio of 46.03% fulfilled within 114.94 days on average. Previously, Jason Wittes worked at NORTHLAND CAPITAL MARKETS, AEGIS, BREAN.

Jason Wittes’s has documented 133 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SYK, Stryker at 09-Nov-2023.

Wall Street Analyst Jason Wittes

Analyst best performing recommendations are on LMAT (LEMAITRE VASCULAR).
The best stock recommendation documented was for LMAT (LEMAITRE VASCULAR) at 7/29/2015. The price target of $13 was fulfilled within 2 days with a profit of $1.18 (9.98%) receiving and performance score of 49.92.

Average potential price target upside

ARAY Accuray orporated ATEC Alphatec Holdings GMED Globus Medical STXS Stereotaxis SYK Stryker TFX Teleflex orporated ZBH Zimmer Biomet Holdings VAR Varian Medical Systems BWAY Brainsway Ltd NUVA NuVasive NVCR Novocure Ltd MASI Masimo CLDX Celldex Therapeutics LMAT LeMaitre Vascular MDWD Mediwound Ltd PGNX Progenics Pharmaceuticals ENOV Enovis Corp

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$4.39 (168.20%)


1 years 8 months ago

0/2 (0%)

$4.94 (239.81%)


2 years 2 months 3 days ago

0/3 (0%)

$7 (140.00%)



$7.39 (283.14%)


2 years 3 months 29 days ago

0/5 (0%)

$5.7 (132.56%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Wittes is most bullish on?

Potential upside of $18.71 has been obtained for GMED (GLOBUS MEDICAL)

Which stock is Jason Wittes is most reserved on?

Potential downside of -$10.03 has been obtained for SYK (STRYKER)

What Year was the first public recommendation made by Jason Wittes?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?